Form 4: Indaptus Therapeutics Director Robert Martell Granted 12,500 Stock Options

Indaptus Therapeutics, Inc. Director Robert Martell was granted 12,500 stock options with an exercise price of $0.33, vesting on June 10, 2026, as disclosed in a recent SEC Form 4 filing.

Summary

• Robert Martell, a Director of Indaptus Therapeutics, Inc. (INDP), was granted 12,500 stock options.
• The options have an exercise price of $0.33 per share.
• The transaction date for the grant was June 10, 2025.
• These options will vest and become exercisable on June 10, 2026.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Mr. Martell directly beneficially owns 12,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between management and shareholder interests, incentivizing long-term performance. It's a standard compensation practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The exercise price of $0.33 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The document indicates a future vesting date of June 10, 2026, for the granted stock options, implying a long-term incentive structure for the director.

Management Comments

• /s/ Robert Martell

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for directors, to attract and retain talent and align their interests with long-term company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across various industries, including biotechnology. Specific comparisons to other companies' director compensation would require detailed analysis of their proxy statements (DEF 14A filings) to assess the size and terms of similar grants relative to company size, performance, and director responsibilities. Without such data, a direct comparison is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• The grant of stock options to Robert Martell, a Director of Indaptus Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Management/Directors: Robert Martell receives a significant equity incentive, tying his personal financial success to the company's stock performance.

Next Steps

• The stock options will vest and become exercisable on June 10, 2026.

Key Dates

Keywords

Indaptus Therapeutics, INDP, Stock Option, Director Compensation, Beneficial Ownership, SEC Form 4, Equity Grant, Robert Martell